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Proton therapy confers substantially lower predicted risk of second cancer compared with photon
therapy. However, no previous studies have used an algorithmic approach to optimize beam angle
or fluence-modulation for proton therapy to minimize those risks. The objectives of this study
were to demonstrate the feasibility of risk-optimized proton therapy and to determine the
combination of beam angles and fluence weights that minimize the risk of second cancer in the
bladder and rectum for a prostate cancer patient. We used 6 risk models to predict excess relative
risk of second cancer. Treatment planning utilized a combination of a commercial treatment
planning system and an in-house risk-optimization algorithm. When normal-tissue dose
constraints were incorporated in treatment planning, the risk model that incorporated the effects of
fractionation, initiation, inactivation, and repopulation selected a combination of anterior and
lateral beams, which lowered the relative risk by 21% for the bladder and 30% for the rectum
compared to the lateral-opposed beam arrangement. Other results were found for other risk
models.
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1. Introduction
Improvements in cancer detection and treatment have led to increased survival rates. In the
United States, the 5-year survival rate for all cancers has increased from about 50%
(1975-1977) to 68% (2003-2009) (Siegel et al 2014). It is estimated that there are 14.5
million cancer survivors in the US and this number is expected to increase to nearly 19
million by 2024 (Desantis et al 2014). Because of the increasing population of long-term
survivors, minimizing the risk of treatment-related late effects, such as the development of a
radiogenic second cancer (Followill et al 1997, Verellen and Vanhavere 1999, Friedman et
al 2010, Berrington de Gonzalez et al 2011, Newhauser and Durante 2011, NCRP 2011),
has become increasingly important.
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Considerable attention has been paid to quantifying and reducing the risk of late effects
following radiotherapy (Newhauser and Durante 2011, NCRP 2011). For example, the use
of proton therapy has been shown to reduce the predicted risk of late effects of radiotherapy
(Brodin et al 2011), including the development of a second cancer (Miralbell et al 2002, Mu
et al 2005, Schneider et al 2006, Fontenot et al 2009, Newhauser et al 2009, Taddei et al
2010, Rechner et al 2012, Arvold et al 2012, Efstathiou et al 2012, Moteabbed et al 2014),
cardiac toxicity (Zhang et al 2013) and fertility complications (Pérez-Andújar et al 2013)
relative to the corresponding risks after photon radiotherapy. In addition, it has been shown
that in-field or field-bordering organs are the largest contributing factor when predicting or
measuring the risk of second cancer after external beam radiotherapy for the prostate
(Fontenot et al 2009, 2010) and for childhood cancers (Diallo et al 2009), including the
craniospinal axis (Newhauser et al 2009). For these reasons, it appears that second cancer
risks could be substantially reduced by developing treatment planning strategies for proton
therapy that minimize the predicted risk to in-field and field-bordering organs. One study
optimized the prescription dose to minimize life years lost following radiotherapy for
medulloblastoma patients by balancing the risk of tumor recurrence and side effects from
treatment (Brodin et al 2014). However, to our knowledge, the literature contains no reports
of optimization of beam angle or fluence modulation to specifically minimize the predicted
risk of second cancer for a fixed prescription dose. Therefore, the feasibility and impact of
risk-optimized treatment planning was previously unknown.
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The aim of this work was to determine whether risk-optimized proton therapy (ROPT) is
feasible and to minimize the predicted risk of second cancer in the bladder and rectum for a
representative prostate cancer patient. To accomplish this aim, we applied risk models from
the literature to patient-specific dosimetric data from a commercial treatment planning
system (TPS) and Monte Carlo simulations. Additionally, we developed a risk-optimized
treatment planning technique for ROPT that optimized proton fluence weights for each of 16
coplanar treatment beam orientations.

2. Methods and materials
2.1 Patient selection and organs at risk
The medical record for a 56-year-old prostate cancer patient was selected for use in this
study. Data were collected in accordance with a protocol that was approved by The
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University of Texas MD Anderson Cancer Center's (MDACC) institutional review board.
The patient previously underwent proton therapy at MDACC for intermediate stage
adenocarcinoma and is representative of the typical prostate cancer patient seen in our
practice. The patient selected for this work was studied previously (Fontenot et al 2009,
Rechner et al 2012), facilitating direct comparisons with those previous works. During CT
simulation and treatment, a water filled balloon was inserted into the patient's rectum to
immobilize the prostate and provide posterior rectal sparing. The clinical target volume
(CTV) included the prostate and proximal seminal vesicles.
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In a previous study, Fontenot et al (2009) reported that the predicted risk of second cancers
in the bladder and rectum contribute most of the overall predicted risk of developing second
cancers following proton radiotherapy for prostate cancer. Therefore, we considered the
bladder and the rectum as organs at risk in this study. For purposes of risk prediction, we
included the bladder wall and rectal wall and excluded their contents in accordance with the
recent recommendations of the International Commission on Radiological Protection
Publication 110 (2008).
2.2 Treatment planning and risk optimization
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Initial treatment planning was completed using a commercial TPS (Eclipse version 9, Varian
Medical Systems, Palo Alto, CA, USA) that was clinically commissioned for proton therapy
(Newhauser et al 2007). 16 passively-scattered proton beams were placed at equal intervals
of gantry angle separation around the patient. Lateral, proximal, and distal margins for each
beam were defined using the methodology described in the literature (Moyers et al 2001)
and used for prostate treatment planning at our institution. Beam angles started at 0 degrees
and were placed at intervals of 22.5 degrees. The individual beams were designed such that
one beam, and any combination thereof, provided uniform coverage of the treatment
volume. The prescribed RBE-weighted absorbed dose was 76 Gy (RBE), where absorbed
dose in Gy was weighted by a generic relative biological effectiveness (RBE) of 1.1
following the recommendations of the International Commission on Radiation Units and
Measurements (2007). Note that for the purposes of this study, namely combining exposures
from therapeutic proton beams and leakage neutrons, we expressed the therapeutic dose in
Gy (RBE) as numerically equivalent to the radiation protection quantity equivalent dose in
Sv. For prescribing doses and evaluating therapeutic aspects of treatment plans, we followed
the recommendations of the International Commission on Radiation Units and
Measurements (2007) regarding quantities and units.
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For each beam of the 16 therapeutic proton beams, the stray neutron dose contributions were
calculated with Monte Carlo simulations (Rechner et al 2012). Neutron absorbed doses were
converted from Gy to equivalent dose in Sv by applying a mean radiation weighting factor
of 10 based on results from previous studies (Zheng et al 2008).
Dose matrices containing primary and stray radiation were exported from the TPS and
Monte Carlo output files and imported into an in-house code for processing (MATLAB
version R2013a, Mathworks, Natick, MA). Processing included summing the proton doses
and neutron equivalent doses on a voxel-byvoxel basis to produce a total equivalent dose
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matrix for each gantry angle. These matrices served as input data for the risk optimization
algorithm.
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The risk optimization method used in this study was implemented in an in-house code and
searched over all possible searched over all possible combinations in the set where beam
weights are positive and sum to 1. Additionally, because of the symmetry of the pelvis,
corresponding left and right beams (at the same angle from 0 degrees) conferred virtually
identical risk. Therefore, corresponding left and right beams (with the exception of the
anterior-posterior and posterior-anterior beams, which did not have corresponding beams)
were constrained to equal one another. The magnitude of relative beam weight variation was
discretized to 0.1 (or 0.05 for each beam in a left/right beam pair). As the algorithm searched
over all combinations, the combination with the lowest risk found yet was flagged as the
provisional best permutation. Additionally, the code tested whether the dose volume
histogram (DVH) constraints used clinically at our institution were met (table 1). Once all
combinations were examined, the best two ROPT plans for each risk model were flagged for
further analysis, namely, the plans that only minimized predicted risk, and those that
minimize predicted risk and satisfied the DVH constraints.
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To calculate the excess relative risk for second cancer induction after radiotherapy for each
tissue (ERRT) for each solution of beam weight combinations, we applied a risk model that
accounts for initiation, inactivation, repopulation, and promotion (iirp), and the effects of
fractionation (Sachs and Brenner 2005, Shuryak et al 2009b, 2009a, 2011). This model
integrates both long- and short-term models. The stochastic short-term model considers the
number of microenvironments called stem cell niches that can be eradicated or initiated to
become pre-malignant. The long-term model assumes that stem cells are located in these
tissue niches, that an initiated stem cell either dies out or initiates a whole niche (i.e.,
forming a premalignant clone), that pre-malignant cells lose carcinogenic potential with age,
and that there is a net proliferation rate of premalignant niches. The iirp risk model was
compiled from two related manuscripts and an erratum (Shuryak et al 2009b, 2009a, 2011)
and ERRT was calculated by
(1)
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where Vi is the volume of the ith voxel (out of N voxels) and VT is the total organ volume.
The term Q1 describes the promotion of existing premalignant stem-cell niches by radiation
and a subsequent loss of carcinogenic potential with time. The term Q2 models the number
of healthy stem cells initiated by radiation, including effects of repopulation and inactivation
during fractionated radiotherapy. Parts Q3 and Q4 model the proliferation of radiationinduced and existing (background) premalignant niches, respectively. The terms Q1 through
Q4 are defined as
(2)

(3)
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(4)

(5)

In equation 3 ISf(D(i)) represents the net outcome of initiation, inactivation, and cell
repopulation during radiation exposure, and Sf(Z,D(i)) represents the probability that a preexisting pre-malignant stem cell niche survives irradiation. ISf(D(i)) and Sf(Z,D(i)) were
calculated according to the stochastic methods described in the manuscripts from Shuryak et
al (2009a, 2011). For a full description of the stochastic part of the risk model, the reader is
referred to the references listed above; however, the equations are also listed below:
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(6)

the term I(i,k) helps to describe the number of cells initiated and is given by
(7)

the clone survival probability is given by
(8)

the term Δ(i,k) is given by

Author Manuscript

(9)

the ratio of stem cells after a radiation fraction to before a radiation fraction is given by
(10)

the number of stem cells after a radiation fraction is given by
(11)
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the number of stem cells before a radiation fraction is given by
(12)

the surviving fraction of cells is after a given radiation dose is given by
(13)
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In equations 1-13 the index i denotes the voxel, and the index k denotes the fraction. The
definitions and values used in equations 6-13 can be found in table 2. In addition, we
assumed that radiation exposure would not reduce the risk of second cancer relative to the
unexposed population and constrained the iirp risk model to have a minimum of 0.
Additionally, in order to span the different possible relationships between dose and risk, we
applied the linear-non-threshold risk model (NRC 2006) and 4 other non-linear risk models
(Lindsay et al 2001, Davis 2004, Sachs and Brenner 2005, Zheng et al 2008, Schneider and
Walsh 2008, Shuryak et al 2009b, 2009a, Schneider et al 2011, Fontenot et al 2009,
Rechner et al 2012). Of those 4 non-linear risk models, the first two models describe a
linear-exponential relationship where after a specified maximum risk the risk decreases
exponentially. The other two non-linear risk models demonstrate a linear-plateau
relationship, where after the maximum risk the risk remains constant with increasing dose.
For both the linear-exponential and the linear-plateau risk relationships, a low and a high
dose for maximum risk were chosen, namely, 10 Sv and 40 Sv (expressed as linearexponential-x and linear-plateau-x, where x denotes the numeric value of maximum risk).
For all risk models, an exposed age of 60 years and attained age of 70 years was assumed.
For these 5 risk models, the formula used to calculate ERRT was
(14)
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where the subscript T denotes the tissue of interest (bladder or rectum), n is the number of
voxels in the tissue, fT is the fractional mass of the subregion of interest compared to the
total mass of the organ for which a risk coefficient is defined (0.2 for the rectum as a
fraction of the whole colon, and 1 for the bladder since the whole bladder was considered)
(Rechner et al 2012), Vi is the volume of the ith voxel, and VT is the volume of the tissue. R
is the risk in the ith voxel in tissue T and is alternately defined as
(15)

(16)

(17)
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Hi is the equivalent dose (Sv) for the given voxel, and for the linear-non-threshold risk
model μT is the tissue-specific risk coefficient (NRC 2006). For the non-linear risk models,
the combination of the parameters μT and αT control the shape of the curve, approximating
the linear-non-threshold model at low doses and determining the dose level for maximum
risk (10 Sv or 40 Sv in this study) (Fontenot et al 2009, 2010). Values for these coefficients
are listed in table 3. In this study it was assumed that minimizing the values of ERRbladder
and ERRrectum were of equal importance during optimization.
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3. Results
Two ROPT treatment plans were created for each risk model, one with and one without
consideration of DVH constraints, for a total of 12 optimized scenarios, of which 4 were
unique (referred to as plans A, B, C and D, figure 1). All ROPT treatment plans provided
clinically adequate coverage of the CTV, where 100% of the CTV received at least the
prescribed dose of 76 Sv.
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The ROPT treatment plan for the iirp risk model consisted of single posterior beam when
DVH constraints were ignored (plan B, figure 1) and consisted of a heavily-weighted
anterior beam and a small contribution from a lateral parallel-opposed pair when DVH
constraints were respected (plan C, figure 1). This anterior plus lateral ROPT treatment plan
(plan C) reduced the ERR by 21% for the bladder and 30% for the rectum when compared
with the standard of care parallel-opposed treatment plan using the iirp risk model. Details
of the ROPT plans are listed in tables 4 and 5.
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For the linear-non-threshold model, the variation in ERRbladder and ERRrectum were plotted
against beam angle (figure 2). The right-left-averaged values are plotted between 0 and 180
degrees for visual clarity. The value of ERRbladder generally decreased as the beam angle
increased from 0 to 180 degrees (from anterior to posterior), whereas the value of ERRrectum
generally increased as the beam angle increased from 0 to 180 degrees. It should be noted
that this type of illustration is applicable only for the linear-non-threshold risk model, where
the linear nature of the model allows the risk from any combination of beam angles to be
found by calculating a weighted average of the risk contributions from each individual
beam. The ROPT treatment plan that minimized second cancer in the bladder and rectum
using the linear-non-threshold model consisted of a lateral parallel-opposed beam pair (plan
A). The result did not change when DVH constraints were applied during optimization.
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When the linear-exponential-10 risk model was used, the minimum ERR was achieved with
a posterior beam (plan B), but when DVH constraints were applied, the lowest ERR was
achieved by a heavily-weighted anterior beam and a small contribution from a lateral
parallel-opposed pair (plan C). This result is qualitatively the same as the result found with
the iirp risk model. When compared with the standard of care parallel-opposed treatment
plan, the ROPT plan (plan C) reduced the risk of second cancer in the bladder by 19% and
the rectum by 34% for the linear-exponential-10 risk model, while meeting normal tissue
DVH constraints. For both the linear-exponential-40 and the linear-plateau-10 risk models,
the ROPT plan was a pair of posterior-oblique beams (plan D); however, this plan did not
meet the DVH constraints. When DVH constraints were included, the ROPT plan selected
for the linear-exponential-40 and linear-plateau-10 risk models was a lateral parallelopposed beam pair (plan A). For the linear-plateau-40 risk model, the ROPT plan was a
lateral parallel-opposed beam pair (plan A), which met the DVH constraints. Summaries of
all ROPT treatment plans are listed in tables 4 and 5.

4. Discussion and conclusion
In this study, we demonstrated the feasibility of including a risk optimization procedure in
the proton treatment planning process and created ROPT plans for a representative prostate
Phys Med Biol. Author manuscript; available in PMC 2016 May 21.
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cancer patient using multiple risk models. When the risk model that accounted for initiation,
inactivation, repopulation, and promotion (iirp) was used, we found that using a
combination of anterior and lateral-opposed beams reduced the risk by 21% in the bladder
and 30% in the rectum when compared to the current standard of care of lateral-opposed
beams alone. We also found that the same anterior and lateral-opposed beam plan reduced
the risk by 19% in the bladder and 34% in the rectum for the linear-exponential risk model
with the lower level of maximum risk (10 Sv). For all other risk models (linear-nonthreshold risk model, both linear plateau risk models, and the linear-exponential risk model
with the higher level of maximum risk (40 Sv)) the standard of care plan of lateral-opposed
beams provided the lowest total risk and met the objectives to minimize acute toxicity.
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The results of this study are of potential clinical significance for several reasons. Others
have investigated minimizing risk through choice of treatment modality (Miralbell et al
2002, Mu et al 2005, Schneider et al 2006, Fontenot et al 2009, Newhauser et al 2009,
Bednarz et al 2010), reduction of stray radiation exposures due to leakage radiation (Tayama
et al 2006, Taddei et al 2008, Brenner et al 2009), optimization of prescription dose (Brodin
et al 2014), or optimizing treatment plans for a metric other than absorbed dose, such as
RBE (Wilkens and Oelfke 2005), linear energy transfer (Grassberger et al 2011), robustness
(Cao et al 2012), or equivalent uniform dose and other radiobiological metrics (Brahme
1999, Wu et al 2002, Choi and Deasy 2002, Thieke et al 2003, Thomas et al 2005,
Penagaricano et al 2005, Kim and Tomé 2006, Widesott et al 2008, Semenenko et al 2008,
Qi et al 2009, Mihaylov et al 2011). There has also been progress on integrating risk
predictions into the TPS for direct analysis (Hartmann and Schneider 2014). However, ours
is the first study to demonstrate algorithmically optimized treatment planning specifically
for second cancer risk while maintaining the dose to the tumor. Future studies could apply
risk-optimized treatment planning to other, more anatomically complex treatment sites, such
as the head and neck, where an algorithmically risk-optimized treatment plan would likely
reduce the predicted risk of second cancer compared with plans prepared according to
current standards of care which do not yet include risk of second cancer in the optimization
process.
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The data in the literature that most closely relates to this study is from the work of Fontenot
et al (2009). It can be estimated from figure 5 of their manuscript that the combined ERR to
in-field organs following proton therapy for prostate cancer ranges from approximately 1 to
6, depending on risk model (linear-exponential-10 at the low end and linear-non-threshold at
the high end), compared with 0.53 to 7.53 in this work. Considering the difference in
methods, namely, the use bladder and rectum contours with or without including the
contents for risk prediction, our results agree very well. Furthermore, in our previous study
(Rechner et al 2012), we reanalyzed their data using the same bladder wall and rectal wall
contours used in our study and found that the ERR from therapeutic radiation for a lateral
parallel- opposed treatment would be 7.45 for the linear-non-threshold risk model. This
agrees even more closely with the value of 7.53 for the combined ERR for second cancer in
the bladder and rectum found in this study.
A limitation of this work is the uncertainty in the relationship between dose and risk of
second cancer, especially the extent of nonlinearities in the dose-risk relationships. There are
Phys Med Biol. Author manuscript; available in PMC 2016 May 21.
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many proposed risk models, such as proposed by Shuryak et al (2009a, 2009b, 2011) (used
in this study) and Schneider et al (2011) that may be particularly appropriate risk models for
risk of second cancer following fractionated radiotherapy, since they incorporate both
biological parameters and epidemiological data. However, there are currently still large
uncertainties with these risk models. We dealt with this uncertainty by performing
sensitivity tests to quantify the effects of nonlinearities and other model characteristics.
Specifically, we applied a variety of plausible risk models that span the likely relationships
between dose and risk of second cancer. What we found in our study is that the qualitative
findings from the linear-exponential-40 and both linear-plateau models agree with those
from the linear-non-threshold model when DVH constraints were applied. The
epidemiological work of Berrington de Gonzalez et al (2011) suggests that the organs
considered in this study likely follow a linear relationship with dose and risk and that the
only organ with clear evidence for a non-linear relationship is the thyroid. If it is true that
the risk of second cancer for the bladder and rectum follows a linear (or semi-linear)
relationship, a lateral-opposed beam pair provides the lowest predicted risk of second cancer
after proton radiotherapy for prostate cancer for the patient studied. However, if future
research reveals that the true relationship between dose and carcinogenesis risk would more
closely follow the iirp or linear-exponential-10 models, the proton treatment plan with the
lowest predicted risk of second cancer in the bladder and rectum that also meets acute
toxicity constraints is the combination of an anterior beam and a lateral parallel-opposed
pair. We would also like to stress that clinical decision making based on risk predictions
should only be performed after risk models have been validated, which is outside the scope
of this work.
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Another limitation of this work is that we only considered the risk of second cancers in the
organs from which we expected the largest contribution to predicted risk (the bladder and
rectum) and excluded risk of cancer in the bone marrow, soft tissue (sarcoma), skin, and
other more distant organs. Furthermore, we did not compare absolute risks nor estimate
severities of cancer in the different organs at risk. Future research could include whole-body
risk optimization, including estimation of severities for each risk endpoint and, perhaps,
patient- or physician-guided prioritization of endpoints. In addition, only one patient was
studied in this work. It should be noted that the ROPT plans presented in this study are
patient-specific and differences in patient anatomy could yield a different optimal plan.
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One of the major strengths of this study is the level of detail of the dose reconstructions.
Doses were reconstructed on patient-specific pelvic anatomy, and included simulations of
both therapeutic and stray neutron dose, using facility- and patient-specific machine settings.
While complete patient-specific neutron dose simulations provided value in this study, an
alternative would be to use an analytical model (Zhang et al 2010) in a clinical setting where
speed is a necessity. Another strength of this study is that the search for the optimal plan was
comprehensive. By analyzing risks for all combinations of beam weighting, our approach
was immune to being trapped in local minima and potentially missing the global minimum.
Future work could include utilization of a different algorithm, for example the conjugate
gradient method, which might enable ROPT for very large problem sizes such as intensity-
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modulated proton therapy. However, care would need to be taken to ensure the identification
of the global minimum.
In conclusion, this study demonstrated that risk-optimized treatment planning is feasible for
proton therapy. We found that the optimal treatment plan to reduce the predicted risk of
second cancer for a prostate cancer patient depended on the risk model. Future development
will be needed to validate risk models, implement these methods clinically, to extend them
to optimize other late effects (Zhang et al 2013, Pérez-Andújar et al 2013, Brodin et al
2014), and to consider additional host and treatment related factors.
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Axial slice showing risk-optimized proton therapy (ROPT) treatment plans with and without
DVH constraints applied during the planning process for 6 different risk models, which
yielded only 4 unique plans (A-D). Specific details regarding plans A-D are listed in tables 4
and 5. In general, Plan A was selected using the linear non-threshold risk model and met all
DVH constraints for normal tissue. Plans B and D were selected using risk models that
assumed decreased risk at high doses due to inactivation, but did not meet the DVH
constraints. When DVH constraints were considered for these models, Plan C was selected
as the compromise between acute toxicity and risk of second cancer.
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Figure 2.
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Predicted excess relative risk (ERR) versus beam angle (θ) for second cancer in the bladder
and rectum using the linear-non-threshold risk model. ERR values are the average of the
values from the left and right corresponding beam angles (the beam angle listed and the
contralateral beam mirrored over the sagittal axis) because of the symmetry of the pelvic
anatomy. For this figure, the beam weight for the angle of interest is set to 1, with all other
beam weights set to 0.
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Table 1

Author Manuscript

Dose volume histogram (DVH) constraints used clinically at our institution (units of Gy) and for this study
(units of Sv), where the tissue should receive no greater than the dose specified to the volume of tissue
specified.

Author Manuscript

Normal Tissue

Dose (Gy or Sv)

Percent Volume (%)

Rectum

40

60

45

50

60

40

70

15

75.6

10

78

5

Bladder

70

15

Rectal Wall

60

70

79

30

Femoral Heads

45

50
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Table 2

Author Manuscript

Parameters and their assumed values in the iirp risk model in our study (Shuryak et al 2009a, 2009b, 2011).
Indices i and k denote the ith voxel and kth fraction. If the value column is left empty, that signifies that the
value varies with voxel or fraction. If two values are listed, the first corresponds to the bladder and the second
corresponds to the rectum.
Parameter

Value

Unit
voxels

Vi

cc

Volume of a voxel

cc

Volume of a tissue

Vt

Number of voxels in a tissue

Y

0.626, 0.0717

Sv−1

Characterizes the dose-dependency of promotion

X

0.151, 2.40

years/Sv

Characterizes the dose-dependency of initiation

Author Manuscript

δ

1.68, 0.0193

b

0.282, 0.217

years−1

Ty

10

years

Time since exposure

Tx

60

years

Age at exposure

10−3

years−1

Describes homeostatic regulation of the number of pre-malignant stem cells per niche
Pre-malignant niche replication rate

D(i)

Sv

Total dose for all fractions to a given voxel

d(i,k)

Sv

Fraction dose to a given voxel

K

38

I(i,k)

v

fractions
Sv

F(i,k)

n-

Definition

N

602.6, 251.2

or +(i,k)

S(i,k)

Number of fractions
Helps to describe the number of cells initiated
Clone survival probability

cells

Number of stem cells present before irradiation

cells

Normal stem cell number before (-) and after (+) fraction

-

Surviving fraction of cells

Author Manuscript

Z

602.6, 251.2

cells/niche

α

0.25

Sv−1

Stem cell radiation inactivation constant

β

0.025

Sv−2

Stem cell radiation inactivation constant

λ

0.05, 0.10

time−1

n-(K+1)

v

cells

F(K)

1

-

Carrying capacity for pre-malignant stem cells per niche

Maximum net proliferation rate (repopulation)
Number of stem cells at large time after exposure
Clone survival probability after last fraction
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Table 3

Author Manuscript

Tissue-specific risk parameters for second cancer induction 10 years after exposure at 60 years of age for the
other 5 risk models.

μT

αT

Linear-non-threshold

Linear-exponential-10

Linear-exponential-40

Linear-plateau-10

Linear-plateau-40

Bladder

0.40

0.49

0.46

0.51

0.47

Colon

0.51

0.61

0.57

0.65

0.58

Bladder

-

0.09

0.025

0.25

0.068

Colon

-

0.09

0.025

0.25

0.068
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Table 4

Author Manuscript

Details describing risk-optimized proton therapy (ROPT) treatment plans for prostate radiotherapy. Results
were obtained without normal tissue DVH constraints for linear and non-linear risk models. Axial slices of the
treatment plans are shown in figure 1.
Without DVH Constraints
Risk model

Plan description

Gantry Angles (degrees)

Beam Weights

ERR bladder

ERR rectum

Plan Label

iirp (Shuryak et al)

Posterior

180

1

0.52

0.10

B

Linear-non-threshold

Lateral parallel-opposed

90, 270

0.5, 0.5

5.46

2.07

A

Linear-exponential-10

Posterior

180

1

0.21

0.06

B

Linear-exponential-40

Posterior oblique

157.5, 202.5

0.5, 0.5

1.08

0.96

D

Linear-plateau-10

Posterior oblique

157.5, 202.5

0.5, 0.5

0.49

0.39

D

Linear-plateau-40

Lateral parallel-opposed

90, 270

0.5, 0.5

1.74

0.65

A
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Table 5

Author Manuscript

Results from risk optimization, describing which treatment plan confers the lowest predicted risk of second
cancer following prostate radiotherapy. Results were obtained with normal tissue DVH constraints for linear
and non-linear risk models. Axial slices of the treatment plans are shown in figure 1.
With DVH Constraints
Risk model

Plan description

Gantry Angles (degrees)

Beam Weights

ERR bladder

ERR rectum

Plan Label

iirp (Shuryak et al)

Anterior and Lateral
parallel-opposed

0, 90, 270

0.9, 0.05, 0.05

0.73

0.14

C

Author Manuscript

Linear-non-threshold

Lateral parallel-opposed

90, 270

0.5, 0.5

5.46

2.07

A

Linear-exponential-10

Anterior and Lateral
parallel-opposed

0, 90, 270

0.9, 0.05, 0.05

0.32

0.09

C

Linear-exponential-40

Lateral parallel-opposed

90, 270

0.5, 0.5

1.54

0.59

A

Linear-plateau-10

Lateral parallel-opposed

90, 270

0.5, 0.5

0.74

0.27

A

Linear-plateau-40

Lateral parallel-opposed

90, 270

0.5, 0.5

1.74

0.65

A
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